Q2 FY2026 EarningsQ2 FY26 reported a wider-than-expected loss: net loss was $21.7M vs. $18.9M expected, and GAAP EPS was -$0.36 vs. -$0.33 consensus. The miss was primarily driven by a 14.4% negative variance in EBIT ($23.3M loss vs. $20.4M expected), fueled by accelerated clinical trial spending in the ADVANCED-2 and STARBORN-1 programs. Despite the bottom-line miss, the company maintains a robust cash position of $161.9M, providing a runway into 2028 and supporting pivotal data catalysts in Q4 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Protara Therapeutic(TARA) the EBIT is -23.32 M (-40.62%), Miss estimate;the EPS is -0.36 (-2.86%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B40.62%
-0.02B22.92%
-0.00B17.70%
EPSMiss expectations
-0.362.86%
-0.32557.01%
-0.03459.87%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf